Growth Metrics

Eli Lilly (LLY) Free Cash Flow (QoQ) (2009 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 343.58%
Dec 31, 2025 -89.95%
Sep 30, 2025 385.52%
Jun 30, 2025 790.96%
Mar 31, 2025 -84.04%
Dec 31, 2024 -58.59%
Sep 30, 2024 878.13%
Jun 30, 2024 34.34%
Mar 31, 2024 112.99%
Dec 31, 2023 -213.44%
Sep 30, 2023 1,246.94%
Jun 30, 2023 -110.01%
Mar 31, 2023 -8.60%
Dec 31, 2022 -27.35%
Sep 30, 2022 96.91%
Jun 30, 2022 -62.35%
Mar 31, 2022 9.51%
Dec 31, 2021 52.21%
Sep 30, 2021 -7.15%
Jun 30, 2021 -0.21%
Mar 31, 2021 2.69%
Dec 31, 2020 -3.75%
Sep 30, 2020 -36.14%
Jun 30, 2020 1,683.72%
Mar 31, 2020 -92.42%
Dec 31, 2019 31.32%
Sep 30, 2019 53.69%
Jun 30, 2019 653.90%
Mar 31, 2019 -89.80%
Dec 31, 2018 -43.07%
Sep 30, 2018 53.37%
Jun 30, 2018 503.75%
Mar 31, 2018 -84.62%
Dec 31, 2017 -20.65%
Sep 30, 2017 14.61%
Jun 30, 2017 736.45%
Mar 31, 2017 -89.30%
Dec 31, 2016 11.33%
Sep 30, 2016 24.01%
Jun 30, 2016 409.72%
Mar 31, 2016 -160.63%
Dec 31, 2015 -25.90%
Sep 30, 2015 14.70%
Jun 30, 2015 365.07%
Mar 31, 2015 -126.49%
Dec 31, 2014 -25.98%
Sep 30, 2014 74.52%
Jun 30, 2014 1,036.56%
Mar 31, 2014 -94.43%
Dec 31, 2013 -27.33%
Sep 30, 2013 15.79%
Jun 30, 2013 577.56%
Mar 31, 2013 -81.37%
Dec 31, 2012 -12.74%
Sep 30, 2012 20.93%
Jun 30, 2012 56.07%
Mar 31, 2012 -57.26%
Dec 31, 2011 -11.01%
Sep 30, 2011 -0.19%
Jun 30, 2011 76.91%
Mar 31, 2011 -45.65%
Dec 31, 2010 23.96%
Sep 30, 2010 -9.24%
Jun 30, 2010 111.00%
Mar 31, 2010 -52.72%
Dec 31, 2009 55.72%
Sep 30, 2009 51.58%
Jun 30, 2009 1,180.17%